MaxCyte Statistics
Total Valuation
MaxCyte has a market cap or net worth of $222.11 million. The enterprise value is $95.16 million.
Important Dates
The next estimated earnings date is Tuesday, August 5, 2025, after market close.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MaxCyte has 106.42 million shares outstanding. The number of shares has increased by 1.68% in one year.
| Current Share Class | 106.42M |
| Shares Outstanding | 106.42M |
| Shares Change (YoY) | +1.68% |
| Shares Change (QoQ) | +0.38% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 95.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.90 |
| Forward PS | 5.16 |
| PB Ratio | 1.11 |
| P/TBV Ratio | 1.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.23, with a Debt / Equity ratio of 0.09.
| Current Ratio | 12.23 |
| Quick Ratio | 11.29 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -19.63% and return on invested capital (ROIC) is -13.82%.
| Return on Equity (ROE) | -19.63% |
| Return on Assets (ROA) | -13.12% |
| Return on Invested Capital (ROIC) | -13.82% |
| Return on Capital Employed (ROCE) | -23.58% |
| Revenue Per Employee | $330,482 |
| Profits Per Employee | -$366,579 |
| Employee Count | 114 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.71 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.77% in the last 52 weeks. The beta is 1.04, so MaxCyte's price volatility has been similar to the market average.
| Beta (5Y) | 1.04 |
| 52-Week Price Change | -43.77% |
| 50-Day Moving Average | 2.41 |
| 200-Day Moving Average | 3.44 |
| Relative Strength Index (RSI) | 51.61 |
| Average Volume (20 Days) | 890,022 |
Short Selling Information
The latest short interest is 3.56 million, so 3.35% of the outstanding shares have been sold short.
| Short Interest | 3.56M |
| Short Previous Month | 3.54M |
| Short % of Shares Out | 3.35% |
| Short % of Float | 3.74% |
| Short Ratio (days to cover) | 3.02 |
Income Statement
In the last 12 months, MaxCyte had revenue of $37.68 million and -$41.79 million in losses. Loss per share was -$0.40.
| Revenue | 37.68M |
| Gross Profit | 30.48M |
| Operating Income | -51.22M |
| Pretax Income | -35.43M |
| Net Income | -41.79M |
| EBITDA | -46.92M |
| EBIT | -51.22M |
| Loss Per Share | -$0.40 |
Full Income StatementBalance Sheet
The company has $138.27 million in cash and $18.82 million in debt, giving a net cash position of $119.45 million or $1.12 per share.
| Cash & Cash Equivalents | 138.27M |
| Total Debt | 18.82M |
| Net Cash | 119.45M |
| Net Cash Per Share | $1.12 |
| Equity (Book Value) | 199.41M |
| Book Value Per Share | 1.88 |
| Working Capital | 143.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$31.46 million and capital expenditures -$1.50 million, giving a free cash flow of -$32.96 million.
| Operating Cash Flow | -31.46M |
| Capital Expenditures | -1.50M |
| Free Cash Flow | -32.96M |
| FCF Per Share | -$0.31 |
Full Cash Flow StatementMargins
Gross margin is 80.91%, with operating and profit margins of -135.94% and -110.92%.
| Gross Margin | 80.91% |
| Operating Margin | -135.94% |
| Pretax Margin | -110.92% |
| Profit Margin | -110.92% |
| EBITDA Margin | -124.53% |
| EBIT Margin | -135.94% |
| FCF Margin | n/a |
Dividends & Yields
MaxCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.68% |
| Shareholder Yield | -1.68% |
| Earnings Yield | -18.82% |
| FCF Yield | -14.84% |
Analyst Forecast
The average price target for MaxCyte is $9.00, which is 291.30% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 291.30% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 31.33% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MaxCyte has an Altman Z-Score of 7.19 and a Piotroski F-Score of 1.
| Altman Z-Score | 7.19 |
| Piotroski F-Score | 1 |
